CG
TPTX

Cutler Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Cutler Group’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,200
Closed -$90K – 5836
2022
Q2 		$90K Sell
1,200
-600
-33% -$26.7K 0.01% 1507
2022
Q1 		$48K Buy
1,800
+800
+80% +$26.9K ﹤0.01% 2288
2021
Q4 		$47K Sell
1,000
-1,100
-52% -$49.2K ﹤0.01% 2449
2021
Q3 		$139K Hold
2,100
– – 0.01% 1646
2021
Q2 		$163K Buy
+2,100
New +$155K 0.01% 1489
2020
Q2 		– Sell
-600
Closed -$26K – 5093
2020
Q1 		$26K Hold
600
– – ﹤0.01% 2145
2019
Q4 		$37K Buy
600
+400
+200% +$19K ﹤0.01% 1843
2019
Q3 		$7K Buy
+200
New +$8.71K ﹤0.01% 2873

Cutler Group's TPTX Position: Q3 2022 in Review

Cutler Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 1,200 shares — an estimated $90K sold.

Cutler Group first reported a position in TPTX in Q3 2019 and held it in 8 quarters. The position peaked at $163K in Q2 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Cutler Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 1,200 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $90K.
  • Cutler Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 8 quarters.
  • Cutler Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $163K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.